COMMUNIQUÉS West-GlobeNewswire

Keryx Biopharmaceuticals to Webcast its Presentation at the Cowen 38th Annual Healthcare Conference on March 12, 2018
06/03/2018
BOSTON, March 06, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ: KERX ), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced it will [...]
Otonomy to Present at Cowen and Company Health Care Conference
06/03/2018
SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC ), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that David A. Weber, Ph.D., [...]
Strongbridge Biopharma plc to Present at the Cowen and Company 38th Annual Healthcare Conference and the Oppenheimer 28th Annual Healthcare Conference
06/03/2018
DUBLIN, Ireland and TREVOSE, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP ), a global commercial-stage biopharmaceutical company focused on the development and commercialization of [...]
BioCorRx to Exhibit at the Addiction Executives Industry Summit in Ponte Verde Beach, FL
06/03/2018
ANAHEIM, CA, March 06, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the [...]
Clearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion
06/03/2018
ALPHARETTA, Ga., March 06, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD ), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today [...]
Genetic Technologies Limited: Project Shivom Strategic Alliance
06/03/2018
MELBOURNE, Australia, March 06, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ: GENE ) (“ Company ”, “ GTG ”) a diversified molecular diagnostics company; provider of BREVAGen plus ®, a first-in [...]
Transactions in relation to share buyback program
06/03/2018
Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Nicox : Aperçu des activités en 2018 et résultats financiers 2017 estimés
06/03/2018
Communiqué de presse Nicox : Aperçu des activités en 2018 et résultats financiers 2017 estimés Commercialisation aux Etats-Unis depuis décembre 2017 de VYZULTA TM (solution ophtalmique de latanoprostène bunod), 0,024% [...]
Nicox provides 2018 Outlook and 2017 Estimated Financial Results
06/03/2018
Press Release Nicox provides 2018 Outlook and 2017 Estimated Financial Results VYZULTA TM (latanoprostene bunod ophthalmic solution), 0.024%, marketed by partner Bausch + Lomb in the U.S. since December 2017 ZERVIATE TM [...]
ERYTECH to Host Fourth Quarter and Full Year 2017 Conference Call and Business Update
06/03/2018
ERYTECH to Host Fourth Quarter and Full Year 2017 Conference Call and Business Update Lyon (France), March 6, 2018 - ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company [...]
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana
06/03/2018
First launch in Latin America Basel, Switzerland, March 06, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that partner Grupo Biotoscana S.L. ("GBT") has launched Basilea's hospital antibiotic Zevtera ® ( [...]
Novartis' Xolair® recommended in new global chronic urticaria guideline
06/03/2018
Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], is the only therapy recommended by the guideline for patients unresponsive to antihistamines[2] Xolair is [...]
argenx to Present at Cowen & Company 38th Annual Health Care Conference
06/03/2018
March 6, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
Arcturus Therapeutics Calls on Proposed Director Nominees to Respond to Constructive Board Outreach
06/03/2018
SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT ), a leading RNA medicines company, today issued the following statement regarding the previously announced process for members of [...]
Immutep Announces United States Patent Grant for IMP701 Antibody
06/03/2018
SYDNEY, Australia, March 05, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ: IMMP ) (“Immutep”, the “Company”) announces the grant of patent no. 9,908,936 entitled “Antibody molecules to LAG-3 and uses [...]
HealthEquity Sets Date to Announce Year-end Results
05/03/2018
DRAPER, Utah, March 05, 2018 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY ) (“HealthEquity” or the “Company”), the largest HSA non-bank custodian, today announced that it plans to release its fourth quarter and [...]
Proteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational Vonapanitase
05/03/2018
WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO ), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular [...]
MPX Bioceutical Corporation to Host Investor Conference Call on March 8, 2018
05/03/2018
TORONTO, March 05, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (CSE:MPX) (OTC:MPXEF) today announced that it will hold a conference call to provide an operational and financial update to investors. The call [...]
Amarin Announces Closing of Underwriter’s Purchase of Additional Shares
05/03/2018
BEDMINSTER, N.J., and DUBLIN, Ireland, March 05, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN ) today announced that, in connection with its previously announced underwritten public offering of American [...]

Pages